Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions. These regulatory documents offer detailed insight into the company’s financial condition, risk factors, governance, and product development activities.
CapsoVision’s filings include periodic reports that present net revenue from sales of its CapsoCam Plus capsule endoscopy system, costs of revenue, operating expenses for selling and marketing, research and development, and general and administrative functions, as well as information on cash and cash equivalents and stockholders’ equity. Current Reports on Form 8-K disclose material events such as quarterly financial results, executive appointments or departures, and key regulatory submissions, including applications to the FDA for 510(k) clearance and Breakthrough Device Designation.
On Stock Titan, each new filing from EDGAR is surfaced in near real time and paired with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-page documents, users can review concise highlights of items such as results of operations, changes in leadership, or updates on clinical and regulatory programs for products like CapsoCam Plus, CapsoCam Colon, and CapsoCam UGI.
Investors can also use this page to locate disclosures related to equity structure, the company’s initial public offering, and compensation or appointment details for senior executives, as reported in 8-K filings. By combining direct access to original SEC documents with AI-generated explanations, this section helps users understand how CapsoVision’s regulatory and financial reporting reflects the evolution of its AI-enabled capsule endoscopy business.
CapsoVision, Inc. (CV) director Joanne Carol Imperial reported the receipt of 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU converts into one share of common stock and the RSUs are scheduled to vest on December 31, 2025. The reported acquisition shows 2,887 shares beneficially owned following the grant on a direct basis at a reported price of $0. The Form 4 was signed by an attorney-in-fact and filed on 09/17/2025. No other transactions or derivative instruments are reported.
CapsoVision insider report: Julia S. Gouw, a director of CapsoVision, Inc. (CV), was granted 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU represents the contingent right to receive one share of the issuer's common stock, and the RSUs are scheduled to vest on December 31, 2025. Following the reported transaction the filing shows 2,887 shares beneficially owned directly attributable to these RSUs. The RSUs have an indicated price of $0 in the filing, and the Form 4 was signed by an attorney-in-fact on behalf of Ms. Gouw on 09/17/2025. No other transactions or derivative securities are reported in this filing.
Michele Harari, a director of CapsoVision, Inc. (CV), reported changes in her beneficial ownership related to transactions dated 09/15/2025. The filing shows a disposition of 56,156 shares of common stock and an acquisition of 2,887 Restricted Stock Units (RSUs), each RSU representing the contingent right to one share. The RSUs were granted on 09/15/2025, carry a $0 acquisition price, and are scheduled to vest on December 31, 2025. The form notes earlier reporting of 187,000 shares on a Form 3 (filed July 1, 2025) and states those amounts reflect a 1-for-3.33 reverse stock split effected July 2, 2025 in connection with the issuer's IPO. The Form 4 was signed by Attorney-in-Fact on 09/17/2025.
CapsoVision, Inc. reporting person Rebecca Ann Petersen acquired 24,834 shares of common stock and holds stock options adjusted for a recent reverse split. The Form 4 shows a purchase of 24,834 shares at $0.3663 per share on 08/18/2025, resulting in 24,834 shares beneficially owned directly. The filing also reports two option grants (7,507 and 17,327 underlying shares) with an exercise price of $0.3663, exercisable through 10/31/2031 and 03/22/2032; the options’ share counts and exercise price reflect a 1-for-3.33 reverse stock split tied to the issuer’s IPO. One option is fully vested and the other is partially vested. The Form 4 was filed late due to an administrative error.
CapsoVision reported a transformative quarter highlighted by a completed IPO and continued operational challenges. The company completed an initial public offering in July 2025, selling 5,629,978 shares at $5.00 per share for gross proceeds of approximately $28.1 million and net proceeds of about $23.4 million. As of June 30, 2025, the company had approximately $1.1 million in cash and an accumulated deficit of $140.4 million. The financials for the six months ended June 30, 2025 show an operating loss of $10,033, a net loss of $10,000, and net cash used in operating activities of $9,512. Management disclosed substantial doubt about going concern.
The company executed a 1-for-3.33 reverse stock split effective July 2, 2025, converted outstanding preferred stock into common stock prior to the IPO, and increased authorized common shares to 300 million. Regulatory and product updates include a 510(k) filing for CapsoCam Colon in Q2 2025 targeting FDA clearance in early 2026 and a development agreement with Canon for CMOS sensors with up to $4.1 million in fees. Material weaknesses in internal controls were identified with remediation in progress.
FAQ
What is the current stock price of CapsoVision (CV)?
What is the market cap of CapsoVision (CV)?
